

# Tool for Influenza Pandemic Risk Assessment (TIPRA)

**Version 2 Release**

**January 2020**



Tool for Influenza Pandemic Risk Assessment (TIPRA), second edition

ISBN 978-92-4-003318-4 (electronic version)

ISBN 978-92-4-003319-1 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO Tool for Influenza Risk Assessment (TIPRA). Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

## Contents

Abbreviations and acronyms .....	7
What's new in TIPRA version 2 .....	8
Introduction .....	8
Background .....	8
Risk assessment .....	9
Need for a pandemic influenza risk assessment tool .....	10
Target users and beneficiaries .....	12
Objectives and scope of TIPRA.....	13
Triggers for use .....	13
Risk question of the influenza virus that will be assessed .....	14
Difference between version 1 and version 2 .....	15
Criteria for use of TIPRA to assess an animal influenza virus that has not yet caused a human infection .....	15
Limitations and cautions for use .....	16
Conducting a risk assessment .....	17
Bibliography .....	33
Appendix A. Tool development process .....	35
Appendix B. Risk element guide .....	38
Appendix C. Virus profile for risk assessment.....	50
Appendix D. Virus scoring sheet .....	51
Appendix E. Risk assessment data analysis.....	52

## Acknowledgements

Akiko Kamata, Food and Agriculture Organization of the United Nations (FAO), Italy

Alexander Ryzhikov, State Research Centre of Virology and Biotechnology, Russia Federation

Andrew Clements, USAID, Switzerland

Andrew Hill, BAE System CORDA, United Kingdom of Great Britain and Northern Ireland

Armen Donabedian, Health and Human Services, United States of America

Charles Todd Davis, WHO Collaborating Centre, Centers for Disease Control and Prevention, United States of America

Chi-Kyeong Kim, Korean Centers for Disease Control and Prevention, Republic of Korea

Christina Ahlstrom, EPI-Interactive, United States of America

Christina Bancej, Public Health Agency, Canada

David Swayne, Southeast Poultry Research Laboratory, Department of Agriculture, United States of America

Dayan Wang, WHO Collaborating Centre, CNIC, China

Eeva Broberg, European Centre for Disease Prevention and Control, Sweden

Florette Treurnicht, National Institute for Communicable Diseases, South Africa

Gabriele Neumann, University of Wisconsin-Madison, United States of America

Gounalan Pavade, The World Organisation for Animal Health (OIE), France,

Hala Esmat Tolba, Independent consultant, Egypt

Ian Barr, WHO Collaborating Centre, Victorian Infectious Diseases Reference Laboratory, Australia

Irma Lopez-Martinez, Ministry of Health, Mexico

Jacqueline Katz, WHO Collaborating Centre, Centers for Disease Control and Prevention, United States of America

Javier Montiel Perdomo, Ministry of Health, Mexico

Jill Banks, Animal and Plant Health Agency, United Kingdom of Great Britain and Northern Ireland

John McCauley, WHO Collaborating Centre, Francis Crick Institute, United Kingdom of Great Britain and Northern Ireland

Kisoon Kim, Korean Centers for Disease Control and Prevention, Republic of Korea

Madhur Dhingra, Université Libre de Bruxelles, Belgium

Malik Peiris, Hong Kong University, Hong Kong Special Administrative Region, China

Malinee Chittaganpitch, Department of Medical Sciences, Ministry of Public Health, Thailand

Mandeep Chadha, National Institute of Virology, India

Marwa Mohamed Amin Abd Rabou, Ministry of Health, Egypt

Nancy Cox, independent consultant, United States of America

Pasi Penttinen, European Centre for Disease Prevention and Control (ECDC), Sweden

Phan Trong Lan, Pasteur Institute, Vietnam

Richard Webby, WHO Collaborating Centre, St Jude Children's Hospital, United States of America

Rodney Daniels, WHO Collaborating Centre, Francis Crick Institute, United Kingdom of Great Britain and Northern Ireland

Ron Fouchier, Erasmus MC, Netherlands

Saba Qasmieh, independent consultant, United States of America

Sharon Calvin, Canadian Food Inspection Agency, Canada

Sherein Galal Khoulosy, Animal Health Research Institute, Egypt

Sophie Von Dobschuetz, Food and Agriculture Organization, Italy

Steve Burke, Centers for Disease Control and Prevention, United States of America

Susa Trock, Centers for Disease Control and Prevention, United States of America

Sylvie Van der Werf, Institut Pasteur, Unit of Molecular Genetics of RNA viruses, France

Talat Mokhtari Azad, Tehran University of Medical Sciences, Iran (Islamic Republic of)

Thomas Weaver, Rapporteur, Republic of Korea

Tsutomu Kageyama, WHO Collaborating Centre, National Institute of Infectious Diseases (NIID), Japan

William Ampofo, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana

### **World Health Organization**

Amal Barakat, Regional Office for the Eastern Mediterranean

Leila Bell, Regional Office for Western Pacific, Manila, the Philippines

Aspen Hammond, Global Influenza Programme, WHO headquarters

Belinda Herring, Regional Office for Africa

Magdi Samaan, Global Influenza Programme, WHO headquarters

Katelijan Vandemaele, Global Influenza Programme, WHO headquarters

Andrea Vicari, Regional Office for the Americas

Reina Yamaji, Global Influenza Programme, WHO headquarters

Wenqing Zhang, Global Influenza Programme, WHO headquarters

## Abbreviations and acronyms

ADCC	Antibody Dependent Cellular Cytotoxicity
GIP	Global Influenza Program
GISRS	Global Influenza Surveillance and Response System
HAI/HI	Hemagglutination Inhibition
IRAT	Influenza Risk Assessment Tool
NA	Neuraminidase
NIC	National Influenza Centres
PIRM	Pandemic Influenza Risk Management
ROC	Rank Order Centroid
TE	Technical Experts
TIPRA	Tool for Influenza Pandemic Risk Assessment
US CDC	United States Centers for Disease Control and Prevention
VN	Virus Neutralisation
WHO	World Health Organization
WHO CC	WHO Collaborating Centre for reference and research on influenza

## Tool for Influenza Pandemic Risk Assessment (TIPRA)

### What's new in TIPRA version 2

The launch of TIPRA Version 2 was in April 2020. The scope and calculation process of an overall risk in TIPRA version 2 have diverged from TIPRA Version 1. First, Version 1 was designed for use on a novel influenza virus which has caused at least one human infection. Version 2 enables risk assessment of animal influenza viruses that have not caused human infection but are still of public health importance. Second, Version 1 employed a gateway approach based on set levels of population immunity to determine viruses with pandemic potential. Version 2 removed this gateway approach and instead included Population Immunity as two separate risk elements weighted in likelihood and impact bringing the total number of risk elements to 10 in version 2, versus 9 in TIPRA Version 1. Third, the ranking and weights of TIPRA Version 1 risk elements were revisited and changed. Overall, likelihood and impact scores between Version 1 and Version 2 would be different; 9 elements in the former and 10 elements in the latter. However, the relative pandemic risk of different viruses to each other is expected to remain similar. Furthermore, TIPRA technical experts (TE) reviewed individual risk elements definitions and criteria of TIPRA version 1. The definitions and criteria provide specificity to the risk elements so that TE can operate from a common understanding when making point estimates within the numerical scale of risk for each risk element under consideration. The TIPRA TE representing each risk element generated revision and established a final consensus version through discussion and debate. Each risk category in individual risk stratifications were refined in version 2 to reduce the scope of subjectivity and minimize the score variations.

### Introduction

#### Background

Influenza pandemics are unpredictable but recurring events that can have consequences on human health and economic well-being worldwide. An influenza pandemic occurs when an influenza A virus to which most humans have little or no existing immunity acquires the ability

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24820](https://www.yunbaogao.cn/report/index/report?reportId=5_24820)

